Table 1: Volume and thickness of the bone-cartilage unit, femoral head volume and osteophyte area in healthy subjects (HS), osteoarthritis (OA) and rheumatoid Arthritis (RA) patients.

	Healthy subjects (n = 12)	Osteoarthritis (n = 12)	Rheumatoid Arthritis (n = 6)	ANOVA	OA vs RA	HS vs RA	HS vs OA
		Mean [95%CI]			P - value		
Age (years)	62[60;65]	62 [59;65]	63[60;65]	0.984	—	—	—
Gender (M:F)	6:6	6:6	3:3	1.000	—	—	—
Femoral head volume (cm ³)	52.0[39.6;64.3]	43.6[37.3;50.0]	41.1[33.6;48.7]	0.233	—	—	—
Articular cartilage volume (cm ³)	7.4[5.9;8.9]	5.1[4.0;6.1]	2.9[1.6;4.3]	<0.001	0.012	<0.001	0.021
Articular cartilage thickness (μm)	1413 [1244;1582]	1134 [931;1338]	721[403;1040]	<0.001	0.029	<0.001	0.086
Subchondral bone thickness (μm)	227[172;282]	406[285;527]	409[186;632]	0.021	1.000	0.099	0.034
Calcified cartilage thickness (μm)	108[81.1;143]	119[94.1;151]	56.6[25.3;127]	0.016†	0.017	0.046	1.000
Osteophyte area (mm ²)	8.8[2.2;35.7]	70.9[41.4;121]	49.2[4.7;513]	0.008†	1.000	0.073	0.006

Data are presented as mean [95%CI]. Statistical significance was found using one-way ANOVA. The Post-hoc Bonferroni test was used to identify intergroup differences. †Data not normally distributed was log-transformed and presented as geometric mean [95%CI].

Conclusion: Patients with secondary osteoarthritis due to rheumatoid arthritis had thinner articular cartilage and calcified cartilage but were otherwise not significantly different from patients with primary osteoarthritis. Thus, the inflammatory joint in rheumatoid arthritis was associated with a more pronounced loss of cartilage than the degenerative joint disease in primary osteoarthritis. The thicker calcified cartilage in primary osteoarthritis has been attributed to endochondral ossification; this does not seem to be the case in rheumatoid arthritis.

Acknowledgement: The authors are grateful for the technical assistance of Jette Barlach and Rita Ullerup. This work was financially supported by the Danish Rheumatism Association.

Disclosure of Interests: Rasmus Klose-Jensen: None declared, Anne Friesgaard Christensen: None declared, Louise Brøndt Hartlev: None declared, Lene Warner Thorup Boel: None declared, Mogens Berg Laursen: None declared, Kresten Krarup Keller Speakers bureau: Have received speaking fee from Pfizer, Ellen Margrethe Hauge Grant/research support from: Have received grants from Roche and Novartis, outside the submitted work., Speakers bureau: Have received personal fees from MSD, Pfizer, UCB and Sobi

DOI: 10.1136/annrheumdis-2019-eular.1409

AB0797

GRANULYSIN MEDIATED CYTOTOXICITY AND ITS SERUM CONCENTRATION IN PATIENTS WITH KNEE OSTEOARTHRITIS

^{1,2}Gordana Laskarin^{*}, Tatjana Kehler^{2,3}, Viktor Persic^{4,5}, Merica Aralica³, Božena Ćurko-Cofek⁶, Marija Rogoznica⁷, Ivan Rosovic⁴, Tamara Kauzlaric-Zivkovic⁴, Sandra Rusac-Kukic⁴, Daniel Rukavina^{6,8}. ¹Faculty of Medicine, Department of Physiology and Immunology, Rijeka, Croatia; ²Specialized Hospital "Thalassotherapy-Opatija", Department of Rheumatology, Opatija, Croatia; ³Faculty of Health Studies, Department of Medical Rehabilitation, Rijeka, Croatia; ⁴Specialized Hospital "Thalassotherapy-Opatija", Opatija, Croatia; ⁵Faculty of Health Studies, Rijeka, Croatia; ⁶Faculty of Medicine, Department of Physiology and Immunology, Rijeka, Croatia; ⁷Specialized Hospital "Thalassotherapy-Opatija", Department of Rheumatology, Opatija, Croatia; ⁸University of Rijeka, Department of Biotechnology, Dept. Biomedical Sciences in Rijeka, Rijeka, Croatia

Background: In OA joint, synovial membrane contain immunocompetent cells (1-4), which produce predominantly pro-inflammatory cytokines (2,5), justifying the name "osteoarthritis" and directing the development of disease towards mild systemic inflammatory condition (6). Granulysin (GNLY) is mediator of cellular immunity expressed in T and NK cells in 15 kDa precursor and 9 kDa cytotoxic forms (2). It is regulated by interleukin 15. We investigated GNLY expression in peripheral blood lymphocytes and GNLY mediated apoptosis *in vitro*, serum concentration of IL-15 and the correlation of GNLY expression with intensity of the pain in the knee of OA patients and with 6-minute walk distance.

Objectives: Women with knee OA (20), and healthy control (17) were medically examined, and their blood samples tested. All of them signed informed consent before medical sampling of peripheral blood (PB).

Methods: Visual analogue scale (VAS) of pain and results of 6-minute walk test were noticed in all participants. Peripheral blood mononuclear cells were isolated by gradient density centrifugation and intracellular GNLY labeling in CD3-CD56+NK cells, CD3+CD56- T cells and CD3+CD56+ NKT cells was performed and analyzed by flow cytometry. NK cells' apoptotic activity against NK sensitive K-562 cells was measured in 18-hour PKH-26 (red) cytotoxicity assay with evaluation of propidium

iodide-/annexin V+ target cells by flow cytometry. In some samples anti-GNLY and/or anti-perforin antibodies were added. IL-15 concentration was measured by ELISA. Nonparametric Kruskal-Wallis and Mann-Whitney U-test, as well as Spearman correlation test were used for statistical evaluation.

Results: In lymphocytes of OA patients GNLY expression and NK cell-mediated apoptosis of K-562 cells did not differ significantly from the healthy control. In OA patients only, RC8 antibody against cytotoxic GNLY molecule significantly decreased apoptosis of K-562 cells. RF10 anti-15 kDa GNLY did not show such effect. Anti-perforin antibody completely abolished apoptosis in both groups tested and the effects of additionally added RC8 or RF10 anti-GNLY antibodies were not observed. Serum IL-15 concentration in healthy controls and OA patients was low and did not show statistically significant difference. GNLY expression in lymphocytes, and particularly in NK subset, positively correlated with VAS of pain and 6-minutes walking distance.

Conclusion: In OA patients, GNLY mediated apoptosis is involved in apoptosis of NK sensitive K-562 cells *in vitro* and might be involved in the killing of damaged joint cells *in vivo* after direct contact.

REFERENCES

- [1] Lindblad S, Hedfors E. Arthritis Rheum. 1987;30(10):1081-8.
- [2] Wojdasiewicz P, et al. Mediators Inflamm. 2014;561459.
- [3] Leheita O, et al. Egypt J Immunol 2005;12:113-24.
- [4] Huss RS, et al. Arthritis Rheum. 2010;62:3799-805.
- [5] Imamura M, et al. Int J Inflamm. 2015;2015:329792.
- [6] Maldonado M, Nam J. Biomed Res Int. 2013;2013:284873.

Acknowledgement: The research was financed by the University of Rijeka Science Support No. Uniri-biomed-18-110 -1248 to Gordana Laskarin and by hospital „Thalassotherapy-Opatija“.

Disclosure of Interests: Gordana Laskarin Speakers bureau: Yes, at the professional meetings, Tatjana Kehler Speakers bureau: At some congresses and meetings, Viktor Persic Speakers bureau: At some meetings and congresses, Merica Aralica: None declared, Božena Ćurko-Cofek: None declared, Marija Rogoznica: None declared, Ivan Rosovic: None declared, Tamara Kauzlaric-Zivkovic: None declared, Sandra Rusac-Kukic: None declared, Daniel Rukavina: None declared

DOI: 10.1136/annrheumdis-2019-eular.6079

AB0798

GENDER DIFFERENCES IN DURATION OF SYMPTOMS AND PREOPERATIVE EXPECTATIONS IN TOTAL KNEE ARTHROPLASTY PATIENTS

¹Daisy Latijnhouters^{*}, Claudia Leichtenberg¹, Rob Nelissen¹, Willem Jan Marijnissen², Pieter-Jan Damen³, Thea Vliet Vlieland⁴, Maaik Gademans⁵, In addition to authors, the study group consist of: H. van der Linden-van der Zwaag, B. Kaptein, LUMC; S. Vehmeijer, Reinier de Graaf Hospital, R. Onstenk, Groene Hart Hospital, S. Verdegaa, Alrijne Hospital, H. Kaptein, LangeLand Hospital. ¹LUMC, Orthopaedics, Leiden, Netherlands; ²Albert Schweitzer Hospital, Orthopaedics, Dordrecht, Netherlands; ³Waterland Hospital, Orthopaedics, Purmerend, Netherlands; ⁴LUMC, Orthopaedics, Rehabilitation and Physiotherapy, Leiden, Netherlands; ⁵LUMC, Orthopaedics and Clinical Epidemiology, Leiden, Netherlands

Background: The literature suggests that women with knee osteoarthritis (OA) perceive greater disability and a lower functional level before total